Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 19 of 19 for “"Radioimmunotherapy"”.
-
Radioimmunotherapy using 186Relabeled humanized monoclonal antibodies.
Contains fulltext : 58759.pdf (Publisher’s version ) (Open Access)
-
Improved mehtods and reagents for pretargeted radioimmunotherapy of cancer
Pretargeted radioimmunotherapy (PRIT) of cancer improves upon conventional radioimmunotherapy (RIT) by decoupling the pharmacokinetics of the targeting agent and the radioisotope. In order to improve upon PRIT, we have considered variables such as treatment setting and methodology, the transport …
-
Pretargeted cancer radioimmunotherapy and radioimaging using antibodies and antibody fragments
… diagnosis and therapeutics. In traditional radioimmunotherapy (RIT), tumor targeting antibodies are directly conjugated with radioisotopes and depending on the radionuclides's properties, the direct labeled antibodies can be used for diagnostic or therapeutic purposes. However, one of the …
-
Radioimmunotherapy in an Immunocompetent Tumor Model utilizing a 177Lu-mAb
Radioimmunotherapy (RIT) is a therapeutic strategy in which radionuclides are conjugated to monoclonal antibodies that bind to tumor-associated antigens in the tumor, so that the decay of the radionuclide takes place inside the tumor. The aim of the research presented in this thesis was to …
-
The Development of Novel Radioimmunoconjugates for the PET Imaging and Radioimmunotherapy of Cancer
… strategies, 2) immunoPET imaging, and 3) radioimmunotherapy. This dissertation will attempt to comprehensively cover each of these categories through a series of studies, protocols, and reviews. For the bioconjugation strategies, we will describe the development of a novel site-selective …
-
Radioimmunotherapy of Metastatic Disease - Studies of Alpha- and Beta-particle-Emitting Radionuclides in a Preclinical Model
In radioimmunotherapy, monoclonal antibodies (mAbs) are used as a targeting agent carrying a toxic payload consisting of radionuclides. This treatment allows the irradiation of small lesions, even on the microscopic level. In the present work, two radionuclides with different properties were used. …
-
Development and Characterization of B7-H3-Targeted Radioimmunotherapies For The Treatment of Solid Tumors
<p>Radioimmunotherapy involves the selective targeting of therapeutic radionuclides to cancer-associated cell surface antigens using monoclonal antibodies. Radioimmunotherapy has been successful in treating hematologic cancers, such as non-Hodgkin’s Lymphoma. However, treatment of solid tumors by …
-
The effect of temperature on the bystander effect as examined in human prostate carcinoma cells with alpha particle irradiation
… boron neutron capture therapy (BNCT) and tumor radioimmunotherapy and could provide a means to improve these therapies.
-
Direct and indirect effects of alpha-particle irradiations of human prostate tumor cells
… involved radiation therapies such as radioimmunotherapy and BNCT. This project consists of an engineering part and a biological part. In the engineering part, an apparatus for alpha-particle irradiation of cells was designed and constructed. Dosimetry of this irradiator was conducted. …
-
In vitro evaluation of cytotoxicity and cellular uptake of alternating copolymers for use as drug delivery vehicles
… imaging), and radioiodine (nuclear imaging and radioimmunotherapy) to the backbone. Attachment of hydrocarbon or perfluorocarbon sidechains provides amphiphilicity to produce the multimodal self-assembling micelles. Additionally, encapsulation procedures for chemotherapeutic agents, doxorubicin …
-
Protein engineering for targeted delivery of radionuclides to tumors
… modeling to develop a novel pretargeted radioimmunotherapy (PRIT) approach for the treatment of cancer. In PRIT, a bifunctional antibody is administered and allowed to bind to a cancer antigen. After sufficient tumor uptake of the antibody, a small molecule carrying a radionuclide is …
-
Combination therapy studies with the vascular disruptive agent combretastatin-a4-phosphate (CA4P)
… & carboplatin (UKCTC-207) or 131Iodine anti- CEA radioimmunotherapy (A5B7) was studied. CA4P toxicity was mild and similar to single agent studies - fatigue, tumour pain, flushing, pruritis, headache and hypertension. The DLT was ataxia. A5B7 combination therapy led to dose limiting …
-
Crystallographic studies of interactions between ligands and DNA oligonucleotides
… potential agents in radiotherapy, phototherapy, radioimmunotherapy or photoimmunotherapy, and the structure of the precursor. In all of the examined complexes the ligand binds to the minor groove but not all halogen substituents refine to 100% occupancy. The refined occupancies of the halogen …
-
Biodistribution Studies of 64Cu-DOTA-Cetuximab after Intraperitoneal and Intravenous Injection in a Malignant Ascites Mouse Model of Human Gastric Carcinoma
Intraperitoneal (i.p.) radioimmunotherapy (RIT) may be a promising treatment strategy for intraperitoneally-confined malignant diseases including malignant ascites (MA) in gastric cancer. We conducted a comparative biodistribution study of 64Cu-DOTAcetuximab in subcutaneous (SQ) tumor and MA mouse …
-
Re-Designing Cancer Immunotherapy to Enhance Anti-Tumor Immunity
Immunotherapy has transformed the field of oncology. However, clinical challenges of toxicity and low response rate offer opportunities to develop novel, rational strategies to integrate into current clinical oncology treatment. To address these challenges, we designed a novel local mesenchymal …
-
Leveraging Bio-Inspired Molecules for Cancer Theranostics
… for diagnostic imaging, theranostic imaging, and radioimmunotherapy.</p>
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… theranostics for SPECT/PET imaging and for radioimmunotherapy. We developed domain-specific anti-HER2 antibody-drug conjugates (ADCs) trastuzumab-PEG6-DM1 and pertuzumab-PEG6-DM1. Conjugation using bifunctional chelators p-SCN-DFO and p-SCN-DOTA afforded DFO-trastuzumab-PEG6-DM1 and …
-
Einflussgrößen der Nephrotoxizität eines Radiotracers am Beispiel der Radioimmuntherapie mit 188Re-anti-CD66
Die Nephrotoxizität ist die wichtigste Nebenwirkung bei Applikation von Radioimmunkonjugaten zur Konditionierung des Knochenmarks bei der Leukämiebehandlung. Die Auswirkungen der Unsicherheiten bei der Dosisbestimmung der Niere, insbesondere durch individuelle Nierenmasse und regionale …
-
Hochdosis-Chemotherapie gefolgt von einer myeloablativen Hochdosis-Radioimmuntherapie (HD-RAIT) mit Iod-131-Rituximab und peripherer Stammzelltransplantation (SCTx) bei primär refraktären und rezidivierten Non-Hodgkin-Lymphomen
Einleitung: Ziel der Phase-II-Studie war die Überprüfung der Machbarkeit eines Tandem-Konzeptes mit einer initialen Hochdosistherapie mit BEAM mit SCTx gefolgt von einer myeloablativen HD-RAIT mit Iod-131-Rituximab und SCTx. Methoden: In die Studie eingeschlossen wurden 19 Patienten mit …